STRATFORD, Conn., May 8, 2026
KUBTEC Scientific has launched the XCELL® TomoRad™ x-ray irradiator, a next-generation image-guided radiotherapy (IGRT) system designed to improve preclinical cancer research workflows through faster imaging, lower radiation exposure, and more accessible targeted radiation technology. The company introduced the new platform during the annual meeting of the American Association of Cancer Researchers (AACR), positioning the XCELL TomoRad as a transformative advancement for laboratories conducting radiation oncology and translational cancer research.
The newly launched system incorporates advanced tomosynthesis-based 3D imaging, enabling researchers to reconstruct detailed three-dimensional images using multiple X-ray projections viewed in 1 mm slices. According to KUBTEC Scientific, the technology provides several advantages over traditional microCT-based systems, including significantly lower sample radiation exposure, faster image acquisition and reconstruction, reduced treatment times, and lower overall operational costs.
Industry experts believe the launch reflects growing demand for more efficient and affordable IGRT systems capable of supporting preclinical oncology studies, radiation biology, immunotherapy research, and translational medicine programs. As cancer research increasingly relies on precise targeted radiation models, laboratories are seeking technologies that combine imaging accuracy with streamlined workflow integration and simplified installation requirements.
XCELL TomoRad Expands Access to Targeted Radiation Research
KUBTEC Scientific stated that existing IGRT-capable systems have traditionally been expensive, difficult to install, and operationally complex, limiting access for many academic and research institutions. The company explained that the XCELL TomoRad was specifically developed to reduce these barriers while enabling broader adoption of precision radiation techniques in preclinical environments.
Advertisement
The system includes integrated Advanced Treatment Planning software, allowing researchers to perform customizable and repeatable radiation dosing with minimal training requirements. Researchers can create highly targeted radiation treatment protocols designed to improve consistency across animal studies while enhancing workflow efficiency.
One of the major innovations introduced with the platform is a patent-pending ultra-fast dose delivery feature known as Mag Mode™. The system automatically positions the sample close to the X-ray source to deliver high-dose radiation in shorter treatment cycles without requiring the expense or space associated with proton beam systems. KUBTEC noted that faster treatment times may also help reduce anesthesia duration and stress exposure for laboratory animals involved in research studies.
Researchers and laboratory specialists say technologies that reduce procedural complexity while improving treatment precision are becoming increasingly important as preclinical oncology programs expand globally.
Imaging and Irradiation Technology Continues Advancing
KUBTEC Scientific has spent more than two decades developing X-ray imaging and irradiation systems for preclinical, agricultural, and laboratory research applications. The company’s broader XCELL product portfolio includes benchtop and free-standing irradiation systems supporting applications in cell research, small animal studies, tissue irradiation, and food safety research.
The company also highlighted the growing role of X-ray irradiation systems as replacements for older gamma and cesium irradiators, which involve radioactive isotopes and additional monitoring requirements. Modern X-ray-based systems are increasingly viewed as safer, more efficient, and easier-to-operate alternatives for many research environments.
KUBTEC Scientific CEO Vikram Butani stated that researchers have consistently requested technologies capable of balancing accurate targeting with operational simplicity and affordability. The company believes the XCELL TomoRad may help accelerate development of future radiation therapies while improving translational research capabilities that could eventually benefit clinical cancer care.
Preclinical Oncology Technology Market Gains Momentum
The launch of the XCELL TomoRad comes amid increasing investment in radiation oncology technology, AI-assisted imaging systems, and precision preclinical research tools. Analysts expect demand for advanced IGRT platforms to continue rising as pharmaceutical companies, cancer centers, and academic institutions expand translational oncology programs focused on immunotherapy combinations, targeted radiation dosing, and next-generation cancer treatment strategies.
Researchers believe innovations that improve imaging speed, treatment accuracy, and workflow automation may significantly accelerate preclinical study timelines while improving reproducibility in oncology research environments.
Source: KUBTEC Scientific press release
